GeoVax to Present Groundbreaking COVID-19 Vaccine Data at Keystone Symposia

GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present pivotal data on its COVID-19 vaccine candidates at the Keystone Symposia on Vaccinology. The presentations will focus on the cross-reactivity and broad-spectrum immunity of GEO-CM04S1 and GeoVax's multi-antigen vaccine technology, offering new hope in the fight against COVID-19 and its variants.

The first presentation, led by GeoVax Scientist Pratima Kumari, PhD, will detail how MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants from Alpha to Omicron in preclinical models. The second, by Georgia State University Scientist Amany Elsharkawy, PhD, will explore the GEO-CM04S1 vaccine candidate's cross-reactivity against the original SARS-CoV-2 B.1 and Omicron subvariant XBB.1.5.

Mark Newman, PhD, GeoVax's Chief Scientific Officer, emphasized the importance of inducing broadly specific immune responses, particularly T-cell responses to both Spike and Nucleocapsid viral proteins. This approach could benefit populations where current vaccines have fallen short, including immunocompromised patients.

GeoVax's participation in the Keystone Symposia underscores its leadership in developing next-generation vaccines to combat infectious diseases. The event serves as a platform for sharing advancements in vaccinology, with implications for global health preparedness against emerging viral threats.

The data presented by GeoVax could mark a significant step forward in the ongoing battle against COVID-19, offering insights into more effective vaccination strategies for vulnerable populations and the general public alike. As the virus continues to evolve, the need for vaccines that can provide broad and durable protection becomes increasingly critical.